Filing Flows › Xwell (XWEL) › Q2 2026 › vs Q1 2026
Xwell (XWEL) Q2 2026 vs Q1 2026 (quarter over quarter)
Xwell's revenue rose $507K (+8%) from $6.6M in Q1 2026 to $7.1M in Q2 2026. The biggest changes: XpresTest +$554K (+29%); XpresSpa −$26K (-0.6%); Naples Wax −$21K (-4%).
Xwell, Q2 2026: revenue $7.1M (-7% year over year), operating margin -29.4%, net loss $1.9M, operating cash flow −$4.5M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| XpresSpa | $4.2M | $4.2M | −$26K | -0.6% |
| XpresTest | $2.5M | $1.9M | $554K | +29% |
| Naples Wax | $503K | $524K | −$21K | -4% |
| Revenue | $7.1M | $6.6M | $507K | +8% |
| Other income, net | $272K | −$5.6M | $5.9M | — |
| Net loss | $1.9M | $11.0M | −$9.1M | -83% |
| Costs & expenses | $9.3M | $17.6M | −$8.3M | -47% |
| Operating costs | $9.2M | $12.1M | −$2.8M | -23% |
| Income tax | $51K | $0 | $51K | — |
| Cost of revenue | $4.2M | $4.3M | −$88K | -2% |
| SG&A | $4.7M | $7.6M | −$2.9M | -39% |
| Other operating costs | $402K | $172K | $230K | +134% |
| Operating cash sources | $4.8M | $5.7M | −$884K | -16% |
| Depreciation & amortization | $163K | $172K | −$9K | -5% |
| Share-based compensation | $98K | $886K | −$788K | -89% |
| Cash used in operations | $4.5M | $4.6M | −$87K | -2% |
| Net loss absorbed | $1.9M | $11.0M | −$9.1M | -83% |
| Working capital & other | $2.9M | −$5.4M | $8.2M | — |
Questions
How much did Xwell's revenue grow quarter over quarter in Q2 2026?
Xwell's revenue rose $507K (+8%) from $6.6M in Q1 2026 to $7.1M in Q2 2026.
What drove Xwell's revenue change in Q2 2026?
XpresTest +$554K (+29%); XpresSpa −$26K (-0.6%); Naples Wax −$21K (-4%).